

48. (New) A pharmaceutical composition of claim 47, wherein said lag time is about 2 to about 6 hours.

49. (New) A pharmaceutical composition of claim 47, wherein said lag time is about 3 to about 5 hours.

B1
Cont 50. (New) A pharmaceutical composition of claim 47, wherein said lag time is about 3 to about 4 hours.

51. (New) A composition of claim 47 ^{which} sufficient ^{? what is sufficient} to maintain an ^{therapeutically} effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt.

52. (New) A composition of claim 51 ^D sufficient to maintain an effective level of amphetamine base salts in the patient over the course of 12 hours without further administration of amphetamine base salt.

12 53. (New) A pharmaceutical composition of claim 47, wherein said dosage amounts are substantially equal.

54. (New) A composition of claim 48 wherein said dosage amounts are substantially equal.

55. (New) A composition of claim 48 wherein said second dosage form comprises an

enteric matrix or coating.

56. (New) A composition of claim 54 wherein said second dosage form comprises an enteric matrix or coating.

101 (57) (New) An oral pharmaceutical composition for delivery of one or more amphetamine base salts comprising an immediate release dosage form containing a dosage amount of said one or more salts effective to treat ADHD in a human patient, and a second dosage form containing a dosage amount of said one or more salts effective to treat ADHD in a human patient which has a release onset lag time sufficient that the plasma concentration/time curve of said composition has substantially the same shape of that of Figure 7, adjusted proportionally for said dosage amounts.

B1
Cont

58. (New) A pharmaceutical composition of claim 57, wherein said lag time is about 2 to about 6 hours.

59. (New) A pharmaceutical composition of claim 57, wherein said lag time is about 3 to about 5 hours.

60. (New) A pharmaceutical composition of claim 57, wherein said lag time is about 3 to about 4 hours.

61. (New) A composition of claim 57 sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt.

62. (New) A composition of claim 61 sufficient to maintain an effective level of amphetamine base salts in the patient over the course of 12 hours without further administration of amphetamine base salt.

63. (New) A pharmaceutical composition of claim 57, wherein said dosage amounts are substantially equal.

64. (New) A composition of claim 58 wherein said dosage amounts are substantially equal.

65. (New) A composition of claim 58 wherein said second dosage form comprises an enteric matrix or coating.

66. (New) A composition of claim 64 wherein said second dosage form comprises an enteric matrix or coating.

67. (New) An oral pharmaceutical composition for delivery of dosage amounts of one or more amphetamine base salts sufficient to provide an ADHD effective plasma level in said patient for at least 8 hours without further administration of amphetamine base salt and which has a plasma concentration/time curve which is substantially the same as that of Figure 7, adjusted proportionally for said dosage amounts.

68. (New) The composition of claim 47 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

69. (New) The composition of claim 48 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

70. (New) The composition of claim 54 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

B1
Cont
71. (New) The composition of claim 57 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

72. (New) The composition of claim 58 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

D
73. (New) The composition of claim 64 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

74. (New) A composition of claim 19 wherein said delayed release dosage form is released about 3 to about 5 hours after administration.

75. (New) A composition of claim 19 wherein said delayed release dosage form is released about 3 to about 4 hours after administration.

76. (New) A composition of claim 19 wherein said delayed release dosage form is

released about 4 hours after administration.

77. (New) A composition of claim 47 wherein said delayed release dosage form is released about 4 hours after administration.

78. (New) A composition of claim 57 wherein said delayed release dosage form is released about 4 hours after administration.

79. (New) A composition of claim 19 wherein said immediately released amount and said delayed release amount are substantially equal.

B¹
Cont
80. (New) A composition of claim 43 wherein said immediately released amount and said delayed release amount are substantially equal.

81. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 19.

82. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 42.

83. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 44.

84. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 45.

85. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 47.

86. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 48.

87. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 68.

88. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 70.

89. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 57.

B¹
Cort
90. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 58.

91. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 71.

92. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 73.

93. (New) A composition of claim 47 wherein said amphetamine base salt consists essentially of d-amphetamine or consists essentially of l-amphetamine.

94. (New) A composition of claim 47 wherein said amphetamine base salt is a salt of d/l-amphetamine.

95. (New) An oral pharmaceutical composition for delivery of one or more amphetamine base salts comprising an immediate release dosage form containing a dosage amount of said one or

more salts effective to treat ADHD in a human patient, and a second dosage form containing a dosage amount of said one or more salts effective to treat ADHD in a human patient, wherein the plasma concentration/time profile of said composition is substantially the same as that of Figure 7, adjusted proportionally for said dosage amounts.

96. (New) The composition of claim 95 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

B1-
Cont 4

97. (New) A pharmaceutical composition of claim 95, wherein said dosage amounts are substantially equal.

98. (New) A composition of claim 95 sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt.

99. (New) A composition of claim 67 sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt.

100. (New) A composition of claim 99 sufficient to maintain an effective level of amphetamine base salts in the patient over the course of 12 hours without further administration of amphetamine base salt.

101. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 67.

B¹
Cont'd

102. (New) A method of treating ADHD comprising orally administering to a patient in need thereof a composition of claim 95. ~~D~~

Please amend the claims to read as follows:

B²
Cont'd

19. (Amended) An orally administrable pharmaceutical composition comprising:

(a) an immediate release dosage form containing an amount of one or more amphetamine base salts effective to treat ADHD in a human patient; and

(b) a delayed release dosage form containing an amount effective to treat ADHD in a human patient of one or more amphetamine base salts,

wherein said amphetamine base salts are released from the delayed release dosage form beginning 2-6 hours after administration, after which release the maximum plasma concentration of the amphetamine base salts reaches a level greater than any previous level reached after the beginning of said immediate release, and

wherein said composition is sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt. *Plasma*

B³

27. (Amended) The composition of claim 19 wherein the composition includes an amount of amphetamine base salts to provide an effective level thereof in said patient without further administration over a course of twelve hours. ~~D~~

B⁴

35. (Amended) A composition of claim 19 in the form of a capsule, said capsule including the immediate release dosage form and the delayed release dosage form. ~~D~~

B⁵

42. (Amended) The composition of claim 19 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate ~~D~~

monohydrate and amphetamine sulfate.

B5
Critic

43. (Amended) The composition of claim 75 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

44. (Amended) The composition of claim 32 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

45. (Amended) The composition of claim 35 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

46. (Amended) The composition of claim 27 wherein the amphetamine base salts are dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.

IN THE SPECIFICATION:

Please change page 3, fourth paragraph, to read as follows:

B6

Tablets or capsules coated with a hydrophobic wax-surfactant layer, made from an aqueous dispersion of carnauba wax, beeswax, polyoxyethylene sorbitan monooleate, and hydroxypropyl methylcellulose have been used for rapid drug release after a predetermined lag time. However, even though a two-hour lag time was achieved for the model drug theophylline at a higher coating level (60%), three hours were required for a complete release of theophylline after the lag time. (8)